Anabolic steroid-induced hypogonadism

Androgen- or anabolic steroid-induced hypogonadism (ASIH) is no longer confined to professional athletes; its prevalence among young men and teenagers using androgens and/or anabolic steroids (AAS) is rising fast, and those affected can experience significant symptoms.

Excellent review article on a topical area of endocrinology of increasing complexity published in Clinical Endocrinology.

Management of papillary thyroid cancer

Despite an excellent prognosis (99% survival rate at 20 years),  sub-clinical, small, low risk papillary thyroid cancers are often treated aggressively. This review offers an evidence based approach to managing these tumours and looks at the future of alternative surgical techniques and minimally localized invasive therapies such as ethanol ablation and laser ablation.

Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ 2014;348:g3045 doi:10.1136/bmj.g3045


An excellent series of article on hypogonadism in the BMJ.

Smith N, Quinton R. Kallmann syndrome. BMJ 2012;345:e6971

Anonymous, Bhartia M, Ramachandran S. Klinefelter’s syndrome—a diagnosis mislaid for 46 years. BMJ 2012;345:e6938 (note the typo in the Clinicians’ perspective: “hypogonadotrophic hypogonadism” should read “hypergonadotrophic hypogonadism”)

Blevins CH ,Wilson ME. Klinefelter’s syndrome. BMJ 2012;345:e7558

Pitteloud N. Managing delayed or altered puberty in boys. BMJ 2012;345:e7913